Abstract
First-line treatment with immune checkpoint inhibitors (ICIs) is standard of care for advanced RCC. However, most patients will experience disease progression. Belzutifan, a first-in-class HIF-2α inhibitor, has shown durable responses in heavily pretreated RCC. Cabozantinib, a VEGF, AXL, and MET inhibitor, is approved for advanced RCC. The ongoing, open-label, phase 2 LITESPARK-003 study (NCT03634540) investigated belzutifan + cabozantinib in pts with no prior treatment (cohort 1) and pts with prior ICI therapy (cohort 2).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
